Avior Wealth Management LLC Has $4.87 Million Holdings in Abbott Laboratories (NYSE:ABT)

Avior Wealth Management LLC lifted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 38.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 42,700 shares of the healthcare product maker's stock after acquiring an additional 11,768 shares during the period. Avior Wealth Management LLC's holdings in Abbott Laboratories were worth $4,868,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Capital International Investors boosted its stake in Abbott Laboratories by 9.1% in the 1st quarter. Capital International Investors now owns 70,177,564 shares of the healthcare product maker's stock worth $7,976,382,000 after purchasing an additional 5,882,780 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Abbott Laboratories by 5.0% during the second quarter. Ameriprise Financial Inc. now owns 10,675,827 shares of the healthcare product maker's stock worth $1,103,997,000 after buying an additional 508,524 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Abbott Laboratories by 27.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 7,428,752 shares of the healthcare product maker's stock valued at $771,940,000 after acquiring an additional 1,596,835 shares in the last quarter. Diamond Hill Capital Management Inc. raised its holdings in shares of Abbott Laboratories by 8.5% in the third quarter. Diamond Hill Capital Management Inc. now owns 6,683,586 shares of the healthcare product maker's stock valued at $761,996,000 after purchasing an additional 524,683 shares during the last quarter. Finally, Swiss National Bank lifted its position in shares of Abbott Laboratories by 0.5% in the third quarter. Swiss National Bank now owns 5,163,580 shares of the healthcare product maker's stock worth $588,700,000 after purchasing an additional 26,000 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Royal Bank of Canada boosted their price target on shares of Abbott Laboratories from $125.00 to $130.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 8th. Piper Sandler boosted their price target on Abbott Laboratories from $131.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, October 17th. UBS Group raised their target price on shares of Abbott Laboratories from $143.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, October 17th. Oppenheimer started coverage on shares of Abbott Laboratories in a research note on Tuesday, October 8th. They issued an "outperform" rating and a $130.00 price target for the company. Finally, Edward Jones lowered shares of Abbott Laboratories from a "buy" rating to a "hold" rating in a research note on Tuesday, July 30th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $130.07.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, CEO Robert B. Ford sold 141,679 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the sale, the chief executive officer now owns 220,059 shares of the company's stock, valued at approximately $25,617,068.19. The trade was a 39.17 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.47% of the company's stock.

Abbott Laboratories Stock Performance

Shares of ABT stock traded down $1.20 on Wednesday, hitting $115.93. The company's stock had a trading volume of 5,316,801 shares, compared to its average volume of 5,697,852. The stock's 50 day moving average is $115.54 and its 200-day moving average is $109.74. Abbott Laboratories has a fifty-two week low of $99.71 and a fifty-two week high of $121.64. The company has a market capitalization of $201.08 billion, a PE ratio of 35.24, a PEG ratio of 2.73 and a beta of 0.72. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 EPS for the quarter, topping analysts' consensus estimates of $1.20 by $0.01. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.99%. The company's revenue was up 4.9% on a year-over-year basis. During the same quarter last year, the company earned $1.14 EPS. Equities research analysts expect that Abbott Laboratories will post 4.67 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 15th. Investors of record on Tuesday, October 15th were paid a $0.55 dividend. The ex-dividend date was Tuesday, October 15th. This represents a $2.20 dividend on an annualized basis and a yield of 1.90%. Abbott Laboratories's dividend payout ratio (DPR) is 66.87%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.